Effectiveness of effectiveness and Safety of Aripiprazole in schizophrenia
This study is completed in China. It is testing effectiveness and Safety of Aripiprazole for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Aripiprazole may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Aripiprazole, attend study visits with the research team. The registry lists locations in China.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
China · 12 sites
The Fourth People's Hospital of Hefei
Hefei, Anhui
Site status: Not listed — confirm with the team
Beijing Anding Hospital, Capital Medical University
Beijing, Beijing Municipality
Site status: Not listed — confirm with the team
Beijing HuiLongGuan Hospital
Beijing, Beijing Municipality
Site status: Not listed — confirm with the team
Peking University Sixth Hospital
Beijing, Beijing Municipality
Site status: Not listed — confirm with the team
The First Haerbin Psychiatric Hospital
Harbin, Heilongjiang
Site status: Not listed — confirm with the team
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan
Site status: Not listed — confirm with the team
Wuhan Mental Health Center
Wuhan, Hubei
Site status: Not listed — confirm with the team
102 Miltary Hospital of China
Changzhou, Jiangsu
Site status: Not listed — confirm with the team
Shandong Mental Health Center
Jinan, Shandong
Site status: Not listed — confirm with the team
Shanghai Mental Health Center
Shanghai, Shanghai Municipality
Site status: Not listed — confirm with the team
The Fourth People's Hospital of Chengdu
Chengdu, Sichuan
Site status: Not listed — confirm with the team
Hangzhou Seventh People's Hospital
Hanzhou, Zhejiang
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Aripiprazole. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Peking University, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
